Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonacog beta pegol - Novo Nordisk

Next Previous
Drug Profile

Nonacog beta pegol - Novo Nordisk

Alternative Names: 40K PEG-rFIX; Glycopegylated rFIX - Novo Nordisk; La-rFIX derivative - Novo Nordisk; N9 GP; NN 7999; NNC-0156-0000-0009; REBINYN; Rebinyn; Refixia

Latest Information Update: 24 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 11 May 2024 Novo Nordisk completes phase III Paradigm9 trial in Haemophilia B (In adolescents, In adults, In the elderly) in China (IV) (NCT05365217)
  • 17 Nov 2023 Novo Nordisk completes phase III paradigm™5 trial for Haemophilia B (in children) in USA, Canada, Brazil, United Kingdom, Italy, Croatia, France, Germany, Japan, Malaysia, Taiwan (IV) (NCT01467427) (EudraCT2011-000826-31)
  • 21 Feb 2023 Registered for Haemophilia B (Prevention) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top